Monte Rosa Therapeutics, Inc. Common Stock (GLUE) Stock Price
GLUEStock
$9.74−5.53%52W
Market Cap$830.95M
P/E—
PEG Ratio—
Div yield—
Beta1.36
GLUE Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-54.25%
Price vs S&P 500 (4W)-19.23%
VGM Score26.96
GLUE Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.37 | -$0.43 | -17.58%(-$0.06) | |
| Q1 2026 | -$0.38 | -$0.45 | -19.07%(-$0.07) | |
| Q4 2025 | -$0.34 | -$0.55 | -63.38%(-$0.21) | |
| Q3 2025 | -$0.35 | -$0.33 | +6.38%(+$0.02) | |
| Q2 2025 | -$0.36 | -$0.15 | +58.80%(+$0.21) |
GLUE Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.27
4.27
4.27
4.27
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
GLUEMonte Rosa Therapeutics, Inc. Common Stock | D | F | D | 28.9x | -83.9% | — | — | $9.74 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Monte Rosa Therapeutics, Inc. Common Stock
Monte Rosa Therapeutics develops molecular glue degraders (MGDs), a novel class of small molecules designed to selectively degrade disease-relevant proteins by harnessing the body's natural protein destruction mechanisms. Leveraging its proprietary QuEEN platform and AI-driven discovery, the company has assembled a library of over 50,000 MGD candidates. Its lead program, MRT-2359, targets GSPT1 in MYC-driven tumors.